Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the combination of RAD001 and
erlotinib hydrochloride can slow the growth of advanced pancreatic cancer. The safety of this
drug combination will also be studied.
Primary Objectives:
-Determine the overall survival (OS) at 6 months of the combination of erlotinib and RAD001
in patients who have received previous treatment for advanced pancreatic cancer.
Secondary Objectives:
- Determine the progression-free survival (PFS).
- Determine the response rate (RR).